Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 17/20 | 0.41 |
| ▸ | PLK3 | Q9H4B4 | 11/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL577918 | 0.87 | PLK1 (0.46) | PLK1PLK3IKBKECDK2CYP2C9 | |
| SCHEMBL577919 | 0.86 | PLK1 (0.46) | PLK1PLK3IKBKECDK2CYP2C9 | |
| SCHEMBL8929156 | 0.85 | PLK1 (0.45) | PLK1PLK3IKBKECDK2CYP2C9 | |
| SCHEMBL578058 | 0.85 | PLK1 (0.41) | PLK1PLK3IKBKECDK2CYP2C9 | |
| SCHEMBL2973598 | 0.79 | PLK1 (0.48) | PLK1PLK3IKBKECDK2CYP2C9 | |
| SCHEMBL4552924 | 0.79 | PLK1 (0.48) | PLK1PLK3IKBKECDK2CYP2C9 | |
| SCHEMBL1373718 | 0.79 | PLK1 (0.46) | PLK1PLK3IKBKECDK2CYP2C9 | |
| SCHEMBL2986978 | 0.76 | ALDH1A1 (0.43) | PLK1PLK3IKBKECDK2CYP2C9 | |
| SCHEMBL8960140 | 0.73 | ALDH1A1 (0.35) | — | |
| SCHEMBL1370903 | 0.73 | KMT2A (0.51) | PLK1PLK3IKBKECDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188134-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110178146-A1 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| US-7829590-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2010-11-09 | — | — | US | disclosed |
| US-20090286840-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178146-A1 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, ABL1, MAP3K5 | PLK1 119/4885PLK3 469/4885IKBKE 376/4885 |
| US-20090286840-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | MAP3K20, ABL1, MAP3K5 | PLK1 119/4885PLK3 469/4885IKBKE 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.